Peripheral Perfusion After UNIFUZOL® Versus Lactated Ringer's in Resolving Septic Shock (UNIRING-OBS SH)
Prospective Multicenter Observational Comparative Cohort Study of Actual UNIFUZOL® (Arginine Sodium Succinate) Versus Lactated Ringer's Use in Adults With Urinary- or Pulmonary-Source Sepsis During the Early Stabilization/Resolving Phase of Septic Shock and Documented Lower-Extremity Atherosclerotic Disease: Peripheral Perfusion, NIRS Vascular Reactivity, and Macro-Microhemodynamic Coherence
Peripheral Perfusion After UNIFUZOL® Versus Lactated Ringer's in Resolving Septic Shock
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Alexey Kovalenko, Doc Biol Sci
- Número de teléfono: 212 +78127108225
- Correo electrónico: science@polysan.ru
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Adults treated in participating intensive care units for urinary- or pulmonary/respiratory-source sepsis with current or recently documented septic shock, documented lower-extremity atherosclerotic peripheral artery disease, early hemodynamic stabilization, ongoing hypoperfusion, and PiCCO Plus already in place for clinical indications. Potentially eligible participants are screened consecutively during active recruitment periods.
Descripción
Inclusion Criteria:
- Age 18 years or older.
- Septic shock by Sepsis-3 currently or documented within the previous 24 hours.
- Urinary or pulmonary/respiratory suspected or confirmed infection source.
- Documented atherosclerotic disease of the lower-extremity arteries.
- Mean arterial pressure at least 65 mm Hg with norepinephrine less than 0.2 micrograms/kg/min and no increase greater than 20 percent or new vasopressor during the previous 30 minutes.
- PiCCO Plus already installed for clinical indications and technically usable.
- At least one ongoing sign of hypoperfusion or microcirculatory dysfunction defined in the protocol.
- Before any study-specific baseline procedure, the treating physician has independently decided that an additional crystalloid infusion is clinically indicated and has selected UNIFUZOL® or lactated Ringer's solution.
- Thenar NIRS-VOT can be performed safely.
- Informed consent or another ethics-board-approved consent process is completed before study-specific procedures.
Exclusion Criteria:
- Hemorrhagic, cardiogenic, or obstructive shock as the leading cause of instability.
- Rapidly increasing vasopressor requirement or need for immediate hemodynamic rescue inconsistent with the protocol-defined stabilization phase.
- Clinically important fluid overload/pulmonary edema for which the treating physician considers additional fluid contraindicated; severe unstable ARDS.
- Active major bleeding or another condition requiring urgent therapy that prevents standardized baseline assessment.
- Expected survival less than 24 hours or limitation of intensive treatment.
- Pregnancy or breastfeeding.
- Participation in an interventional study expected to materially affect hemodynamics.
- Contraindication to any component of the physician-selected fluid.
- Upper-limb ischemia, severe Raynaud phenomenon, local thenar skin injury, or another condition making NIRS-VOT unsafe or uninterpretable.
- Core temperature below 34 degrees Celsius.
- Acute/critical lower-extremity ischemia requiring urgent vascular treatment or severely compromising peripheral assessments.
- Unable to establish Tdecision/T0 or obtain pre-infusion baseline CRT; inability to obtain pre-infusion ReOx excludes the participant from the key NIRS analysis.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: CASE_CONTROL
- Perspectivas temporales: PROSPECTIVE
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
|---|
|
UNIFUZOL® exposure cohort
Participants for whom the treating physician independently selected and actually started UNIFUZOL® at T0. The protocol does not determine indication, dose, rate, duration, repeat administration, or subsequent fluids. |
|
Lactated Ringer's exposure cohort
Participants for whom the treating physician independently selected and actually started lactated Ringer's solution at T0. The protocol does not determine indication, dose, rate, duration, repeat administration, or subsequent fluids. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Capillary Refill Time at 6 Hours
Periodo de tiempo: 6 hours after start (window ±60 minutes)
|
Capillary refill time (CRT) in seconds measured using a standardized distal-finger technique. Two valid measurements are averaged; if they differ by more than 1.0 second, a third measurement is obtained and the median of three is used. The primary statistical comparison adjusts for strictly pre-infusion CRT and prespecified baseline covariates. Lower CRT is considered physiologically favorable. |
6 hours after start (window ±60 minutes)
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Thenar NIRS Reoxygenation Slope at 6 Hours
Periodo de tiempo: 6 hours after start (window ±60 minutes)
|
Post-occlusion reoxygenation slope (ReOx) derived from a standardized thenar near-infrared spectroscopy vascular occlusion test using a frozen common device/software/analysis algorithm. ReOx is analyzed continuously in percent StO2 per second and adjusted for pre-infusion ReOx. Higher ReOx is considered physiologically favorable. |
6 hours after start (window ±60 minutes)
|
|
Sustained Macro-Microhemodynamic Coherent Response
Periodo de tiempo: 6 and 12 hours after start
|
Protocol-defined supportive composite outcome. This measure is reported as a single binary value (Yes/No), which is considered achieved only if ALL of the following criteria are simultaneously met: full macrohemodynamic stability, peripheral/microvascular recovery, and pulmonary/volume safety at both 6 and 12 hours. The composite is not a validated diagnostic criterion and is analyzed as supportive/exploratory. |
6 and 12 hours after start
|
|
Change in Capillary Refill Time Over 24 Hours
Periodo de tiempo: From start through 24 hours
|
Serial CRT at 60 minutes, approximately 2 hours/end of infusion, 6 hours, 12 hours, and 24 hours; analyses include continuous change and trajectory models. |
From start through 24 hours
|
|
Change in ReOx
Periodo de tiempo: From pre-infusion baseline through 24 hours
|
Serial ReOx from standardized NIRS-VOT. |
From pre-infusion baseline through 24 hours
|
|
Change in De-oxygenation slope
Periodo de tiempo: From pre-infusion baseline through 24 hours
|
DeOx from standardized NIRS-VOT (%/min). |
From pre-infusion baseline through 24 hours
|
|
Change in NIRS Vascular Reactivity Over 24 Hours (tissue oxygenation)
Periodo de tiempo: From pre-infusion baseline through 24 hours
|
Tissue oxygenation variables (%) |
From pre-infusion baseline through 24 hours
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Silla de estudio: K.M. Lebedinsky, North-Western State Medical University named after I.I.Mechnikov
- Investigador principal: I. S. Simutis, Adult Intensive Care Unit, L.G. Sokolov North-Western District Scientific and Clinical Center, FMBA of Russia, St Petersburg, Russian Federation
- Investigador principal: A.Yu. Yakovlev, City Hospital No. 38 named after N.A. Semashko
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Procesos Patológicos
- Infecciones
- Síndrome de Respuesta Inflamatoria Sistémica
- Inflamación
- Aterosclerosis
- Arteriosclerosis
- Enfermedades arteriales oclusivas
- Enfermedades vasculares periféricas
- Choque
- Condiciones Patológicas, Signos y Síntomas
- Septicemia
- Enfermedad arterial periférica
- Choque séptico
Otros números de identificación del estudio
Otros números de identificación del estudio
- UNIRING-OBS SHOCK
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .